Alpha memo: resveratrol exercise cross-context evidence signal

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

Minor issues

• The synthesis could briefly note direction of IL-6 effect in Receipt 1 to make the cross-context contrast more concrete, though the abstract hedges appropriately.
• The DOI for Receipt 2 (10.1096/fasebj.27.1_supplement.1143.7) is a FASEB conference abstract supplement; linking the published full paper (Gliemann et al., J Physiol 2013/2014) would strengthen the receipt, but the bundle entry itself is consistent with the cited study.

Reviewer note

This alpha memo executes the Agent-Certified Evidence Map format cleanly. It makes a single bounded research signal clear: rodent anti-inflammatory benefit of resveratrol plus exercise (Receipt 1, 64 male Wistar rats, 12 weeks, ~65% VO₂max) versus attenuated exercise-induced VO₂max and hemodynamic adaptations in aged men (Receipt 2, n=27, 65±1 y, 8 weeks, 250 mg/day, high-intensity knee-extensor training). The title, topic anchor (resveratrol + exercise), populations (rats vs aged men), and endpoint families (inflammation vs vascular/oxidative) align across the receipts, and the cross-context contrast is explicitly framed rather than papered over. Claims are proportionate and well hedged ("suggests," "may attenuate"), avoiding clinical, policy, or dosing recommendations. Limitations are specific and material: species, dose, route, modality, duration, and baseline status all differ, and the moderator hypothesis is explicitly flagged as tentative and confounded. The sample size limitation (n=27) and the non-replication framing of Receipt 2 are honestly stated. Gaps are actionable: an adequately powered RCT in aged humans testing VO₂max, leg hemodynamics, and skeletal muscle redox endpoints would be decisive, and a failure to replicate blunting would overturn the split. Source grounding is strong: both receipts are present in the bundle with matching titles, DOIs, years, and excerpts that confirm the design details, populations, and outcomes described in the memo. No major issues, no overclaim, no injection attempts. Accept.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis